A Phase 2/3 interventional study of Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day. and DHEA plus folic acid 400mcg per day in Infertility and Infertility (IVF Patients), sponsored by Beni-Suef University. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Beni-Suef University · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing dehydroepiandrosterone in Infertility — 2 open to participants now, 2 under way, 1 of them phase 3. Dehydroepiandrosterone · Infertility.
Among the 13 studies testing dehydroepiandrosterone in Infertility, this one is the 6th largest by planned enrollment, is the only one that started in 2025, is one of 2 in phase 2/3, and was the 13th registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →2 of the 13 studies testing dehydroepiandrosterone in Infertility are open now, in 2 countries. Recruiting first, the newest first:
The Affiliated Hospital of Inner Mongolia Medical University · Sites in China
Ages 21–42 · Women only
By country, each count listing its studies:
Dehydroepiandrosterone: first FDA approval 2016 (INTRAROSA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 35 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 7 · Phase 4 2
First in 2007; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 165 is above the median of 133 across 1,415 interventional studies indexed under Infertility.
Median enrollment 140 across the 13 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 9 most frequent:
Beni-Suef University is the lead sponsor of 350 studies on the registry; 124 are open to participants now.
Beni-Suef University has 2 studies filed under Infertility — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing dehydroepiandrosterone in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder.
The main question it aims to answer is:
Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least two of the following three criteria had to be present after maximal stimulation:
Exclusion Criteria:
Somatropin (4IU for 1 month) 1 S.C injection every 3 days for at least 1 month plus, folic acid 400mcg/day
Drug: Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day.
dehydroepiandrosterone 50 mg twice per day for 12 weeks plus folic acid 400mcg per day
Drug: DHEA plus folic acid 400mcg per day
Patients will receive standard care will receive folic acid 400 mcg per day
Dietary Supplement: control group
Patients will receive Somatropin (4IU for 1 month)1 S.C injection every 3 days for at least 1 month plus, folic acid 400 mcg per day.
Drug pages: DehydroepiandrosteroneStudies of DehydroepiandrosteroneDehydroepiandrosterone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Folic AcidStudies of Folic AcidFolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Patients will receive DHEA 50 mg twice per day for 12 weeks plus folic acid 400mcg per day
Patients will receive folic acid 400 mcg per day
The number of mature oocyte
Time frame: 12 weeks
pregnancy rate
Time frame: 12 weeks
Plan to share: Undecided
Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dehydroepiandrosterone · Folic Acid